Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-Confined hepatocellular carcinoma

Hyejung Cha, Hong In Yoon, Ik Jae Lee, Woong Sub Koom, KwangHyub Han, Jinsil Seong

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Before the sorafenib era, advanced but liver-confined hepatocellular carcinoma (HCC) was treated by liverdirected therapy. Hepatic arterial concurrent chemoradiotherapy (CCRT) has been performed in our group, giving substantial local control but frequent failure. The aim of this study was to analyze patterns of failure and find out predictive clinical factors in HCC treated with a liver-directed therapy, CCRT. A retrospective analysis was done for 138 HCC patients treated with CCRT between May 2001 and November 2009. Protocol-based CCRT was performed with local radiotherapy (RT) and concurrent 5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (HAIC), followed by monthly HAIC (5-FU and cisplatin). Patterns of failure were categorized into three groups: infield, intrahepatic-outfield and extrahepatic failure. Treatment failure occurred in 34.0% of patients at 3 months after RT. Infield, intrahepatic-outfield and extrahepatic failure were observed in 12 (8.6%), 26 (18.7%) and 27 (19.6%) patients, respectively. Median progressionfree survival for infield, outfield and extrahepatic failure was 22.4, 18 and 21.5 months, respectively. For infield failure, a history of pre-CCRT treatment was a significant factor (P = 0.020). Pre-CCRT levels of alpha-fetoprotein and prothrombin induced by vitamin K absence or antagonist-II were significant factors for extrahepatic failure (P = 0.029). Treatment failures after CCRT were frequent in HCC patients, and were more commonly intrahepatic-outfield and extrahepatic failures than infield failure. A history of pre-CCRT treatment and levels of pre-CCRT tumor markers were identified as risk factors that could predict treatment failure. More intensified treatment is required for patients presenting risk factors.

Original languageEnglish
Pages (from-to)1069-1077
Number of pages9
JournalJournal of Radiation Research
Volume54
Issue number6
DOIs
Publication statusPublished - 2013 Nov 1

Fingerprint

Chemoradiotherapy
liver
Hepatocellular Carcinoma
cancer
Recurrence
Liver
Treatment Failure
Fluorouracil
Radiotherapy
chemotherapy
Therapeutics
Drug Therapy
radiation therapy
therapy
Vitamin K
prothrombin
phylloquinone
alpha-Fetoproteins
Prothrombin
Tumor Biomarkers

All Science Journal Classification (ASJC) codes

  • Radiation
  • Radiology Nuclear Medicine and imaging
  • Health, Toxicology and Mutagenesis

Cite this

@article{e473993ef4484599a7fa12bccd6da57f,
title = "Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-Confined hepatocellular carcinoma",
abstract = "Before the sorafenib era, advanced but liver-confined hepatocellular carcinoma (HCC) was treated by liverdirected therapy. Hepatic arterial concurrent chemoradiotherapy (CCRT) has been performed in our group, giving substantial local control but frequent failure. The aim of this study was to analyze patterns of failure and find out predictive clinical factors in HCC treated with a liver-directed therapy, CCRT. A retrospective analysis was done for 138 HCC patients treated with CCRT between May 2001 and November 2009. Protocol-based CCRT was performed with local radiotherapy (RT) and concurrent 5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (HAIC), followed by monthly HAIC (5-FU and cisplatin). Patterns of failure were categorized into three groups: infield, intrahepatic-outfield and extrahepatic failure. Treatment failure occurred in 34.0{\%} of patients at 3 months after RT. Infield, intrahepatic-outfield and extrahepatic failure were observed in 12 (8.6{\%}), 26 (18.7{\%}) and 27 (19.6{\%}) patients, respectively. Median progressionfree survival for infield, outfield and extrahepatic failure was 22.4, 18 and 21.5 months, respectively. For infield failure, a history of pre-CCRT treatment was a significant factor (P = 0.020). Pre-CCRT levels of alpha-fetoprotein and prothrombin induced by vitamin K absence or antagonist-II were significant factors for extrahepatic failure (P = 0.029). Treatment failures after CCRT were frequent in HCC patients, and were more commonly intrahepatic-outfield and extrahepatic failures than infield failure. A history of pre-CCRT treatment and levels of pre-CCRT tumor markers were identified as risk factors that could predict treatment failure. More intensified treatment is required for patients presenting risk factors.",
author = "Hyejung Cha and Yoon, {Hong In} and Lee, {Ik Jae} and Koom, {Woong Sub} and KwangHyub Han and Jinsil Seong",
year = "2013",
month = "11",
day = "1",
doi = "10.1093/jrr/rrt034",
language = "English",
volume = "54",
pages = "1069--1077",
journal = "Journal of Radiation Research",
issn = "0449-3060",
publisher = "Japan Radiation Research Society",
number = "6",

}

Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-Confined hepatocellular carcinoma. / Cha, Hyejung; Yoon, Hong In; Lee, Ik Jae; Koom, Woong Sub; Han, KwangHyub; Seong, Jinsil.

In: Journal of Radiation Research, Vol. 54, No. 6, 01.11.2013, p. 1069-1077.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-Confined hepatocellular carcinoma

AU - Cha, Hyejung

AU - Yoon, Hong In

AU - Lee, Ik Jae

AU - Koom, Woong Sub

AU - Han, KwangHyub

AU - Seong, Jinsil

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Before the sorafenib era, advanced but liver-confined hepatocellular carcinoma (HCC) was treated by liverdirected therapy. Hepatic arterial concurrent chemoradiotherapy (CCRT) has been performed in our group, giving substantial local control but frequent failure. The aim of this study was to analyze patterns of failure and find out predictive clinical factors in HCC treated with a liver-directed therapy, CCRT. A retrospective analysis was done for 138 HCC patients treated with CCRT between May 2001 and November 2009. Protocol-based CCRT was performed with local radiotherapy (RT) and concurrent 5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (HAIC), followed by monthly HAIC (5-FU and cisplatin). Patterns of failure were categorized into three groups: infield, intrahepatic-outfield and extrahepatic failure. Treatment failure occurred in 34.0% of patients at 3 months after RT. Infield, intrahepatic-outfield and extrahepatic failure were observed in 12 (8.6%), 26 (18.7%) and 27 (19.6%) patients, respectively. Median progressionfree survival for infield, outfield and extrahepatic failure was 22.4, 18 and 21.5 months, respectively. For infield failure, a history of pre-CCRT treatment was a significant factor (P = 0.020). Pre-CCRT levels of alpha-fetoprotein and prothrombin induced by vitamin K absence or antagonist-II were significant factors for extrahepatic failure (P = 0.029). Treatment failures after CCRT were frequent in HCC patients, and were more commonly intrahepatic-outfield and extrahepatic failures than infield failure. A history of pre-CCRT treatment and levels of pre-CCRT tumor markers were identified as risk factors that could predict treatment failure. More intensified treatment is required for patients presenting risk factors.

AB - Before the sorafenib era, advanced but liver-confined hepatocellular carcinoma (HCC) was treated by liverdirected therapy. Hepatic arterial concurrent chemoradiotherapy (CCRT) has been performed in our group, giving substantial local control but frequent failure. The aim of this study was to analyze patterns of failure and find out predictive clinical factors in HCC treated with a liver-directed therapy, CCRT. A retrospective analysis was done for 138 HCC patients treated with CCRT between May 2001 and November 2009. Protocol-based CCRT was performed with local radiotherapy (RT) and concurrent 5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (HAIC), followed by monthly HAIC (5-FU and cisplatin). Patterns of failure were categorized into three groups: infield, intrahepatic-outfield and extrahepatic failure. Treatment failure occurred in 34.0% of patients at 3 months after RT. Infield, intrahepatic-outfield and extrahepatic failure were observed in 12 (8.6%), 26 (18.7%) and 27 (19.6%) patients, respectively. Median progressionfree survival for infield, outfield and extrahepatic failure was 22.4, 18 and 21.5 months, respectively. For infield failure, a history of pre-CCRT treatment was a significant factor (P = 0.020). Pre-CCRT levels of alpha-fetoprotein and prothrombin induced by vitamin K absence or antagonist-II were significant factors for extrahepatic failure (P = 0.029). Treatment failures after CCRT were frequent in HCC patients, and were more commonly intrahepatic-outfield and extrahepatic failures than infield failure. A history of pre-CCRT treatment and levels of pre-CCRT tumor markers were identified as risk factors that could predict treatment failure. More intensified treatment is required for patients presenting risk factors.

UR - http://www.scopus.com/inward/record.url?scp=84888251653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888251653&partnerID=8YFLogxK

U2 - 10.1093/jrr/rrt034

DO - 10.1093/jrr/rrt034

M3 - Article

VL - 54

SP - 1069

EP - 1077

JO - Journal of Radiation Research

JF - Journal of Radiation Research

SN - 0449-3060

IS - 6

ER -